The life sciences industry intends to make clinical trials more patient-centric. This is where decentralized clinical trials (DCTs) come in. Sponsors should realize the long-term benefits of patient-centric trials and reduce the burden on the patient. DCTs offer a paradigm shift by making modern-day trials more patient-centric instead of sponsor-centric. For sponsors, decentralized trials will also eliminate efforts for data entry, processing, and monitoring. DCTs will provide an accurate, time and cost-effective solution in comparison to the traditional clinical trials. This blog post highlights HCL’s DCT model that provides a clinical platform by combining service, technology, regulatory compliance, and operational aspects. This solution is also capable of managing the pharmacovigilance data along with clinical endpoints. Know more here.
- Industry Left Col
- Industry Right Col